Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat
- PMID: 8895866
- DOI: 10.1016/0306-4522(96)00249-7
Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat
Abstract
The aim of the present study was to analyse whether riluzole, a compound that interacts with the voltage-dependent sodium channel and impairs glutamatergic transmission, would exhibit a neuroprotective activity in a model of Parkinson's disease in the rat. Impaired skilled forelimb use, circling behavior, and altered dopaminergic metabolism of the mesotelencephalic system were evaluated in unilaterally 6-hydroxydopamine-lesioned rats. Riluzole was administered twice 15 min before, and 24 h after, the lesion. Riluzole reduced both the contralateral rotations induced by apomorphine and the ipsilateral ones elicited by amphetamine. Moreover, the decreased dopaminergic metabolism seen after 6-hydroxydopamine injection was attenuated in the riluzole-treated animals, at both the striatal and nigral levels. These biochemical and behavioral results demonstrate the ability of riluzole partially to protect the degeneration of the nigrostriatal dopaminergic neurons induced by the toxin 6-hydroxydopamine. Perhaps, the most striking evidence for the protective effect of riluzole was that this compound improved the skilled paw use, a complex sensorimotor behavior which is not easily ameliorated by palliative therapies such as dopaminergic grafts. These results extend previous data showing that riluzole counteracts the toxicity induced by 1-methyl-4-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in rodent dopaminergic neurons. The use of riluzole may be considered of potential interest for the neuroprotective therapy of Parkinson's disease.
Similar articles
-
Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.BMC Neurosci. 2012 Apr 5;13:38. doi: 10.1186/1471-2202-13-38. BMC Neurosci. 2012. PMID: 22480308 Free PMC article.
-
Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.Neuroscience. 2000;95(2):377-88. doi: 10.1016/s0306-4522(99)00457-1. Neuroscience. 2000. PMID: 10658617
-
Uptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease.Synapse. 2004 Feb;51(2):119-27. doi: 10.1002/syn.10293. Synapse. 2004. PMID: 14618679
-
Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.Brain Res. 2000 Dec 15;886(1-2):82-98. doi: 10.1016/s0006-8993(00)02915-2. Brain Res. 2000. PMID: 11119690 Review.
-
Classic animal models of Parkinson's disease: a historical perspective.Behav Pharmacol. 2019 Jun;30(4):291-310. doi: 10.1097/FBP.0000000000000441. Behav Pharmacol. 2019. PMID: 30216234 Review.
Cited by
-
Absence of a synergic nigral proapoptotic effect triggered by REM sleep deprivation in the rotenone model of Parkinson´s disease.Sleep Sci. 2019 Jul-Sep;12(3):196-202. doi: 10.5935/1984-0063.20190078. Sleep Sci. 2019. PMID: 31890096 Free PMC article.
-
Neurodegeneration and neuroprotection in Parkinson disease.NeuroRx. 2004 Jan;1(1):139-54. doi: 10.1602/neurorx.1.1.139. NeuroRx. 2004. PMID: 15717014 Free PMC article. Review.
-
Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models.J Neurosurg. 2014 Apr;120(4):854-63. doi: 10.3171/2013.12.JNS13641. Epub 2014 Jan 31. J Neurosurg. 2014. PMID: 24484234 Free PMC article.
-
Endocannabinoid 2-arachidonylglycerol protects primary cultured neurons against LPS-induced impairments in rat caudate nucleus.J Mol Neurosci. 2014 Sep;54(1):49-58. doi: 10.1007/s12031-014-0246-2. Epub 2014 Feb 9. J Mol Neurosci. 2014. PMID: 24510751
-
The Disruption of NMDAR/TRPM4 Death Signaling with TwinF Interface Inhibitors: A New Pharmacological Principle for Neuroprotection.Pharmaceuticals (Basel). 2023 Jul 31;16(8):1085. doi: 10.3390/ph16081085. Pharmaceuticals (Basel). 2023. PMID: 37631001 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources